These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15894525)

  • 1. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
    Heymann D; Ory B; Blanchard F; Heymann MF; Coipeau P; Charrier C; Couillaud S; Thiery JP; Gouin F; Redini F
    Bone; 2005 Jul; 37(1):74-86. PubMed ID: 15894525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
    Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
    Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
    Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
    Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
    Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
    Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
    Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
    Battaglia S; Dumoucel S; Chesneau J; Heymann MF; Picarda G; Gouin F; Corradini N; Heymann D; Redini F
    J Bone Miner Res; 2011 Oct; 26(10):2439-51. PubMed ID: 21713986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
    Ory B; Moriceau G; Trichet V; Blanchard F; Berreur M; Rédini F; Rogers M; Heymann D
    J Cell Mol Med; 2008 Jun; 12(3):928-41. PubMed ID: 18494934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
    Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
    Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
    Gouin F; Ory B; Rédini F; Heymann D
    Int J Cancer; 2006 Sep; 119(5):980-4. PubMed ID: 16570273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
    Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.